- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Advancing Pulmonary Arterial Hypertension Care: Overcoming Challenges in Special Populations and Exploring Innovative Approaches
Ioana Preston, MD, highlights treatment considerations for managing PAH in specific patient populations and discusses the unmet needs that can be addressed by novel therapeutic approaches or improved treatment strategies.
EP: 1.Evolving Guidelines for PAH Treatment
EP: 2.New Therapeutic Frontiers in PAH
EP: 3.Addressing Unmet Needs and Disease Progression Challenges in Pulmonary Arterial Hypertension Management
EP: 4.Overcoming Limitations and Barriers Associated with Treating Pulmonary Arterial Hypertension
EP: 5.Breaking Down the PAH Cost Burden
EP: 6.A New Era in PAH Treatment?
EP: 7.Clinical Evidence for Emerging PAH Therapies
EP: 8.Integrating New PAH Therapies into Clinical Practice
EP: 9.Optimizing Complex Pulmonary Arterial Hypertension Care: Enhancing Adherence and Outcomes
EP: 10.FDA Approves Sotatercept for Pulmonary Arterial Hypertension
EP: 11.Overcoming Barriers to Better Patient Outcomes in PAH
EP: 12.Advancing Pulmonary Arterial Hypertension Care: Overcoming Challenges in Special Populations and Exploring Innovative Approaches
EP: 13.Optimizing PAH Care Delivery for Better Outcomes
EP: 14.Addressing Unmet Needs in the PAH Landscape
Video content above is prompted by the following question(s):
- What are the challenges associated with managing pulmonary arterial hypertension (PAH) in specific patient populations, such as those with comorbidities?
- How can the unmet needs in PAH be addressed through the development of novel therapeutic approaches or improved disease management strategies?
Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed
November 20th 2024Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.
Read More
Poor Sleep Quality Associated With Pulmonary Arterial Hypertension
November 14th 2024Most patients with pulmonary arterial hypertension (PAH) suffered from poor sleep quality, and dyspnea was a significant predictor of sleep quality, independent of disease severity, according to this study.
Read More
Refinements to European Strategy Can Improve PAH-CHD Stratification
November 6th 2024When patients were re-classified based on the adjusted thresholds of N-terminal pro-brain natriuretic peptide and 6-minute walk distance and the inclusion of TAPSE rather than right atria area, classification of patients improved significantly.
Read More
PAH Treatment Outcomes Similar Regardless of Diagnosis Time
November 1st 2024The study findings underscore the importance of early initiation of macitentan and tadalafil among patients who have pulmonary arterial hypertension (PAH), and represent a shift in understanding of prognosis based on diagnosis timing.
Read More
